POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today commented on the Centers for Medicare & Medicaid Services’ (“CMS”) Calendar Year 2026 Physician Fee Schedule (PFS) final rule, which reforms Medicare reimbursement for skin substitutes. “CMS’s final rule represents a decisive step toward a more transpare…

You can read the full content here